Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$1.60
-$0.14(-5.56%)
At close: 4:00 PM EST
$1.60
-$0.14(-5.56%)
Day’s Range― - ―
52-Week Range$1.18 - $2.70
Previous CloseN/A
Volume359.61K
Average Volume (3M)1.16M
Market Cap
$383.26M
Enterprise Value$505.47
Total Cash (Recent Filing)$229.43M
Total Debt (Recent Filing)$79.96M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jul 30, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding266,155,800
10 Day Avg. Volume1,433,992
30 Day Avg. Volume1,158,140
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.08Price Target Upside405.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$128.99M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue Ramp & First Positive Gross ProfitA rapid commercial revenue ramp and the first positive gross profit reflect that product demand and pricing can now cover direct costs. Durable improvement in unit economics reduces reliance on R&D/capital funding and supports a sustainable commercial business as volumes scale.
Manufacturing Scale And Cost-efficiency InitiativesDoubling output while holding or lowering headcount and extracting $15M in annualized savings are structural improvements to per‑unit costs. Sustained manufacturing efficiency materially strengthens gross margins and the path to attractive unit economics over the next 2–3 years.
Clinical Efficacy Signals And Expanding Provider CoverageRobust efficacy and a growing provider footprint reduce adoption friction and support payer engagement. Durable clinical and real‑world outcomes plus expanding treatment centers underpin sustainable demand and facilitate geographic scale beyond initial launch markets.
Bears Say
High Cash Burn And Limited RunwayPersistent large negative cash flow and a subtwo‑year runway create structural financing risk. The company will likely need external capital or milestone receipts to fund growth, raising dilution or covenant risks that can constrain strategic flexibility over the next 2–6 months.
Persistently Large Operating And Net LossesVery negative margins indicate the cost base far exceeds current revenues at the company level. Sustained losses limit self‑funding, pressure returns on equity, and mean profitability timing hinges on continued revenue scaling and cost control, leaving execution dependence intact.
Execution Risk: Manufacturing Scale‑up And European AccessScaling manufacturing and securing European reimbursement are structural execution hurdles. Failures or delays in tech transfer or market access would materially slow revenue diversification, keep per‑unit costs elevated, and compress margins over a multiyear horizon.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics’s price range in the past 12 months?
Autolus Therapeutics lowest stock price was $1.18 and its highest was $2.70 in the past 12 months.
What is Autolus Therapeutics’s market cap?
Autolus Therapeutics’s market cap is $383.26M.
When is Autolus Therapeutics’s upcoming earnings report date?
Autolus Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 9 days.
How were Autolus Therapeutics’s earnings last quarter?
Autolus Therapeutics released its earnings results on May 14, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.253 by -$0.017.
Is Autolus Therapeutics overvalued?
According to Wall Street analysts Autolus Therapeutics’s price is currently Undervalued.
Does Autolus Therapeutics pay dividends?
Autolus Therapeutics does not currently pay dividends.
What is Autolus Therapeutics’s EPS estimate?
Autolus Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Autolus Therapeutics have?
Autolus Therapeutics has 266,155,800 shares outstanding.
What happened to Autolus Therapeutics’s price movement after its last earnings report?
Autolus Therapeutics reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.253. Following the earnings report the stock price went down -7.018%.
Which hedge fund is a major shareholder of Autolus Therapeutics?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.08 (405.00% Upside)
$8.08 (405.00% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-41.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.38%
Trailing 12-Months
Company Description
Autolus Therapeutics
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Stock 12 Month Forecast
Average Price Target
$8.08
▲(405.00% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
―
Insiders
0.36% Mutual Funds
0.18% Other Institutional Investors
98.70% Public Companies and
Individual Investors